RFT1-CDG is a rare N-glycosylation disorder. Only 6 children with RFT1-CDG have been described, all with failure to thrive, feeding problems, hypotonia, developmental delay, epilepsy, decreased vision, deafness and thrombotic complications. We report on two young adult siblings with RFT1-CDG, compound heterozygotes for the novel missense mutations c.1222A>G (p.M408V) and c.1325G>A (p.R442Q) in RFT1 gene. Similar to the previously described patients, these siblings have profound intellectual disability but no feeding problems or failure to thrive. Their epilepsy is well controlled and coagulopathy is mild without clinical consequences. In addition, visual acuity is normal in both patients and hearing impairment is present only in one. Our findings extend the phenotype associated with RFT1-CDG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ymgme.2012.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Background: Poor sleep is emerging as an important and modifiable risk factor in the development of dementia. The hypothalamus is the only neuroanatomical site of orexin-producing neurones in the brain and modulates sleep and wakefulness behaviour. Due its small size and lack of defined contrast in conventional neuroimaging acquisitions, relatively little evidence exists as to the role of the hypothalamus in humans in neurodegeneration and sleep quality, and whether it may have mechanistic importance and biomarker candidacy.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Background: Plasma biomarkers may be a non-invasive and cost-effective tool for diagnosing Alzheimer's Disease. Promising markers include amyloid-β-42/40 ratio (Aβ-42/40), glial fibrillary acidic protein (GFAP), and neurofilament-light (NfL). Not much is known about what genetic and environmental factors influence and potentially confound these biomarker levels.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Background: Alzheimer disease (AD) related cognitive decline occurs at relatively young ages in individuals with Down syndrome (DS, early-mid 50s) and in those with autosomal dominant mutations (ADAD, 40-50s). Both groups show similar patterns of amyloid accumulation. We examined if brain volumes are similarly affected by AD pathology in individuals with DS and ADAD.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Background: Exposures to environmental toxicants and pollutants occur at various points along the life course, with mounting evidence that late-life pollution exposure increases risk for neurological disease, including dementia. Although occupational hazards constitute a primary source of modifiable environmental exposure during the working years, there is little research examining the protracted effects of mid-life occupational exposure on late-life dementia risk.
Method: This study leveraged life course data from the Wisconsin Longitudinal Study (WLS) to evaluate the effects of mid-life occupational hazardous exposures on late-life dementia outcomes.
Public Health.
Alzheimers Dement
December 2024
Dowool Health Welfare Center, Namwon, Korea, Republic of (South).
Background: One out of every ten individuals aged 65 or above in Korea experiences dementia, with a total dementia care cost of KRW 18.7198 trillion, or approximately KRW 21.24 million per person.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!